Supplementary Table. Cytogenetic characteristics of CLL patients with a t(14;18) or variant.

Patient / Sample / Mitogen / Karyotype
1 / BM / TPA / 47,XY,+12,t(14;18)(q32;q21),del(18)(q21)[2]/46,XY[8]
2 / BM / TPA / 46,XY,t(14;18)(q32;q21)[7]/46,XY[12]
3 / BM / TPA / 46,XY,t(14;18)(q32;q21)[5]/46,XY[12]
4 / BM / TPA / 47,XY,+12,t(14;18)(q32;q21)[3]/46,XY[1]
5 / BM / TPA / 45,X,-X,t(14;18)(q32;q21)[6]/46,XX[4]
6 / LN / None / 47,XX,+12,t(14;18)(q32;q21)[8]/46,XX[10]
7 / BM / TPA / 46,XY,t(14;18)(q32;q21)[2]/47,idem,+12[2]/46,XY[11]
8 / BM / TPA / 47,XX,+12,der(18)t(14;18)(q32;q21)[7]/46,XX[3]
9 / BM / TPA / 46,XY,t(14;18)(q32;q21)[9]/46,XY[6]
10 / PB / TPA / 46,XY[8]
positive PCR
11 / PB / TPA / 46,XY,t(14;18)(q32;q21)[4]/46,XY[11]
12 / BM / TPA / 38-44,XX,add(9)(q12),-10,del(13)(q13q21),-14,der(15;17)(q10;q10),-17,der(18)t(14;18)(q32;q21),+mar1,+mar2[4]
13 / BM / TPA / 46,XY,t(14;18)(q32;q21)[4]/46,XY[6]
14 / BM / TPA / 46,XY,der(14)t(14;18)(q32;q21)[3]/46,XY[7]
15 / BM / TPA / 47,XY,+12,t(14;18)(q32;q21)[4]/46,XY[11]
16 / BM / TPA / 46,XY,t(14;18)(q32;q21)[7]/46,idem,del(13)(q13q21)[3]
17 / BM / TPA / 46,XX[15].ish t(14;18)(3’LSI IGH+,5’LSI IGH-,5’LSI BCL2+;3’LSI BCL2+,5’LSI BCL2-,5’LSI IGH+)
18 / BM / TPA / 47,XY,+12,t(14;18)(q32;q21)[9]/46,XY[1]
19 / BM / TPA / 47,XY,+12,t(14;18)(q32;q21)[5]/46,XY[5]
20 / PB / TPA / 45,XY,add(6)(q27),-13,del(13)(q12q31),t(14;18)(q32;q21),-18,+mar1[2] /47,XY,+12[1]/46,XY[11]
nuc ish(D12Z3´3)
21 / BM / TPA / 46,XY,del(13)(q13q21),t(14;18)(q32;q22)[4]/46,XY[12]
22 / BM / TPA / 46,XY,t(14;18)(q32;q21)[3]/46,XY[8]
23 / BM / TPA / 46,XX[15].ish t(14;18)(3’LSI IGH+,5’LSI IGH-,5’LSI BCL2+;3’LSI BCL2+,5’LSI BCL2-,5’LSI IGH+)
24 / PB / TPA / 47,XX,+12,t(14;18)(q32;q21)[4]/46,XX[6]
25 / BM / CpG / 46,XX,t(14;18)(q32;q21)[4]/45,idem,der(8)t(8;17)(p12;q23),-17[5]/46,XX[1]
26 / PB / CpG / 46,XY,t(14;18)(q32;q21)[10]
27 / PB / TPA / 46,XY,t(14;18)(q32;q21)[4]/46,XY[18]
28 / BM / TPA / 46,XY,t(14;18)(q32;q21)[1]/46,XY[3]
29 / BM / TPA / 46,XX,t(14;18)(q32;q21)[4]/46,XX[35]
30 / PB / TPA / 46,XY,t(14;18)(q32;q21)[2]/46,XY[14]
31 / PB / TPA and CpG / 46,XY,t(14;18)(q32;q21)[17]/46,idem,t(1;13)(p32;q34)[13]
32 / BM / CpG / 46,XY,t(14;18)(q32;q21)[4]/46,idem,del(6)(q16q22),ins(13;3)(q31;q28q22)[5]/46,XY[1]
33 / BM / TPA / 47,XY,+12,t(18;22)(q21;q11)[2]/46,XY[14]
34 / BM / TPA / 47,XY,+12,t(18;22)(q21;q11)[3]/46,XY[8]
35 / BM / TPA / 47,XX,+12,t(18;22)(q21;q11)[5]/46,XX[4]
36 / BM / TPA / 46,XY,t(18;22)(q21;q11)[6]/46,XY[4]
37 / BM / None / 46,XX,del(13)(q13q21),t(18;22)(q21;q11)[3]/46,XY[7]
38 / BM / TPA / 46,XY,t(2;18)(p12;q21)[8]/46,XY[2]
39 / BM / TPA / 47,XX,+12[4]/47,idem,t(2;18)(p12;q21)[2]/46,XX[4]
40 / PB / TPA / 46,XY,t(2;18)(p12;q21)[6]/46,idem,del(6)(q15q22)[4]

BM, bone marrow; PB, peripheral blood; LN, lymph node; TPA, 12-O-tetradecanoyl-phorbol-13-acetate; CpG, CpG-oligonucleotide and interleukin-2.